In 2024, Thomas, Ernst, and Gabriel joined forces to address the global need for complex and cost-effective organoids to unlock a new era of discovery.
They brought together their unique skills in stem cell biology, drug development, automation, and global business strategy, to build a lasting company to support the future of life science.
Our locations span Rotterdam, Netherlands — the gateway to Europe — and Boston, USA — the biotech heart of America.
CEO and Cofounder
International biotech executive and drug development expert. Developed broad range of medicines from small molecules to cell therapies, taking assets from discovery to market approval. Thomas has challenged biotech conventions by doing a lot with less capital with the goal of making self-sustaining biotech ventures.
CSO and Cofounder
Global leader in stem cell biology and organoid development. Developed some of the most innovative organoid models to study disease pathways and test emerging treatments. Ernst's work has revealed what we can do with organoid models to study disease onset and treatment showing us there is no ceiling to what we can achieve in this field.
Director and Cofounder
Corporate and financial leader who has developed innovative companies counter to market norms. Bought and sold several companies with large value acquisitions. Gabriel's unique mindset and unwavering support has been the key to unlock The Organoid Company platform.